Investigating FDA
This article was originally published in RPM Report
Executive Summary
Three key internal investigators of FDA within the federal government are the Inspector general's office at HHS, the Government Accountability Office and Congress. Top FDA investigators at each of these entities are Nicole Hall and Mary Riordan at the IG; Marcia Crosse and Martin Gahart at GAO and Alan Slobodin on the Health Enrgy & Commerce Committee oversight and investigations staff.
You may also be interested in...
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
Why Plan B Matters
While Barr's attempt to switch the emergency contraceptive Plan B to over-the-counter status is immaterial to the company, the rest of the drug industry can't afford to ignore the controversy, which could jeopardize the renewal of crucial legislation that supports fast and predictable reviews of all new drugs. Moreover, FDA may be reopening old controversies, like whether third parties can force an OTC switch against a brand company's wishes.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.